Breaking Down Meinian Onehealth Healthcare Holdings Co., Ltd. Financial Health: Key Insights for Investors

Investors staring at Meinian Onehealth (002044.SZ) will want to weigh hard facts: revenue slipped to CNY 10.70 billion in FY2024 (down 1.76% y/y) and is guided at only CNY 3.96-4.20 billion for H1 2025 (a 0.12%-5.83% decline y/y), nine‑month 2025 revenue came in at CNY 6.93 billion vs CNY 7.14 billion a year earlier, and trailing twelve‑month revenue is down 2.45%; profitability is strained-FY2024 net income fell to CNY 282.24 million (down 44.18% y/y) and H1 2025 is expected to report a net loss of CNY 192-236 million, while TTM EPS is CNY 0.05 with a P/E near 96 (trailing P/E 69.36, forward P/E 32.55); balance‑sheet and liquidity flags include total debt of CNY 6.69 billion, equity of CNY 8.39 billion (book value per share CNY 1.94), a current ratio of 0.73 and quick ratio 0.67, net cash per share of CNY -1.13, an Altman Z‑Score of 1.67 and a Piotroski F‑Score of 5; valuation metrics show market cap ≈ CNY 19.72 billion, EV CNY 24.99 billion, EV/EBITDA 11.74 and P/S 1.88; growth levers include AI‑related revenue >CNY 215 million in 2024, a 92.35% acquisition in Shandong (April 2025), a one‑year market‑cap gain of 38.69%, and analyst forecasts of ~45.4% EPS and 12.5% revenue CAGR over three years-read on for a line‑by‑line breakdown and what these numbers mean for risk and opportunity.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Revenue Analysis

• H1 2025 revenue guidance: CNY 3.96 billion-CNY 4.20 billion (down 0.12% to 5.83% vs. H1 2024).
• FY 2024 total revenue: CNY 10.70 billion (down 1.76% from CNY 10.89 billion in 2023).
• 9M 2025 revenue (to Sept 30, 2025): CNY 6.93 billion vs. CNY 7.14 billion in 9M 2024.
• Trailing twelve months (TTM) revenue growth: -2.45%.
• Revenue per employee: CNY 274,140 with a workforce of 38,253 employees.
• Market capitalization: ~CNY 19.72 billion; P/S ratio: 1.88.

• Volume mix: health screening volumes remain core but face competition and pricing pressure.
• Service expansion: incremental revenue from higher-margin diagnostic services may be needed to reverse declines.
• Operational leverage: fixed-cost base and large employee count compress per-employee revenue productivity until top-line stabilizes.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Profitability Metrics

• Projected H1 2025 net income: loss of CNY 192 million to CNY 236 million (versus H1 2024 loss of CNY 216 million).
• FY 2024 net income: CNY 282.24 million, down 44.18% from CNY 506.42 million in FY 2023.
• Trailing twelve months (TTM) EPS: CNY 0.05; TTM P/E: 95.98.
• Trailing P/E: 69.36; Forward P/E: 32.55.
• Gross profit margin: 42.19%; operating margin: 8.87%; net profit margin: 2.75%.
• Return on equity (ROE): 5.10%; return on assets (ROA): 3.13%.

• Margin structure: a healthy gross margin (42.19%) suggests core service economics remain attractive, but a steep drop from operating to net margin (8.87% → 2.75%) highlights significant non-operating costs, taxes, or one-off items eroding bottom-line profits.
• Valuation signals: elevated TTM P/E (95.98) versus forward P/E (32.55) implies the market priced in near-term earnings weakness; trailing and forward P/Es (69.36 vs. 32.55) indicate expected earnings recovery priced into forward estimates.
• Returns: ROE of 5.10% and ROA of 3.13% are modest - investors should weigh capital efficiency against sector peers and growth prospects.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) Debt vs. Equity Structure

• Total debt: CNY 6.69 billion
• Equity (book value): CNY 8.39 billion
• Book value per share: CNY 1.94
• Debt-to-equity ratio: 0.80
• Current ratio: 0.73
• Quick ratio: 0.67
• Interest coverage ratio: 2.97
• Net cash per share: CNY -1.13

Key implications for investors:

• Capital structure: with debt at CNY 6.69bn vs. equity CNY 8.39bn, leverage (0.80×) is moderate but meaningful for a healthcare services company.
• Liquidity pressure: current ratio 0.73 and quick ratio 0.67 indicate short-term obligations exceed readily available current assets; working capital management or refinancing could be priorities.
• Interest burden: interest coverage of 2.97x shows the company can cover interest from operating earnings but with limited buffer-sensitive to earnings volatility.
• Net cash position: negative net cash per share (CNY -1.13) signals net indebtedness on a per-share basis, which can constrain strategic flexibility or require capital measures.

Context and further reading: Meinian Onehealth Healthcare Holdings Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Liquidity and Solvency

• Current ratio: 0.73 - potential liquidity shortfall versus near-term obligations.
• Quick ratio: 0.67 - limited immediate liquid resources excluding inventories.
• Interest coverage ratio: 2.97 - earnings provide modest coverage of interest costs.
• Net cash per share: CNY -1.13 - net debtor position per share.
• Altman Z-Score: 1.67 - increased risk of financial distress/bankruptcy (below safe zone).
• Piotroski F-Score: 5 - middling operational/financial strength signaling moderate health.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Valuation Analysis

• Market cap: CNY 19.72 billion
• Enterprise value: CNY 24.99 billion
• Investor expectations: forward P/E (32.55) materially below trailing P/E (69.36), suggesting anticipated profit recovery or one-off impacts in the trailing period

• Profitability signal: elevated trailing P/E implies recent earnings compression or non-recurring items; forward P/E indicates the market expects normalization.
• Cash-flow perspective: P/FCF of 15.82 and EV/FCF of 19.92 show meaningful valuation reliance on future free cash generation-investors should assess cash-conversion trends and capex needs.
• Balance-sheet lens: P/B of 2.36 and high P/TBV of 9.47 indicate a premium for intangibles, goodwill, or service network value inherent in health-check and medical services operations.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Risk Factors

• Net income: expected net loss in H1 2025, confirming ongoing profitability challenges and incomplete recovery from prior periods of weak earnings.
• Revenue trajectory: multi-year negative revenue growth trend, raising questions about top-line resilience and demand for core services.
• Liquidity: current and quick ratios are low (both below 1.0), suggesting constrained short-term liquidity and limited buffer for operational shocks.
• Cash and financing: company reports a negative net cash position, indicating dependence on external financing and elevated refinancing risk in tighter markets.
• Bankruptcy risk metric: Altman Z‑Score = 1.67, a level associated with increased bankruptcy risk and financial distress in corporate credit analysis.
• Firm-level fundamentals: Piotroski F‑Score = 5, a middling score that signals moderate financial health but clear room for operational and balance-sheet improvement.

• Operational risks: continued revenue decline could force service rationalization, clinic closures, or accelerated cost-cutting that harm long-term capacity.
• Refinancing and interest-rate risk: a negative net cash position combined with external borrowing exposes the company to rising financing costs and covenant pressure if markets tighten.
• Regulatory and reimbursement risk: any adverse changes in healthcare policy, pricing, or insurance reimbursement can magnify revenue weakness and margin compression.
• Market confidence: metrics like Altman Z‑Score (1.67) and a middling Piotroski F‑Score (5) may erode investor and creditor confidence, increasing the cost of capital.
• Execution risk: improving the balance sheet and returning to consistent revenue growth will require successful operational initiatives, new patient acquisition, and disciplined capital allocation.

Meinian Onehealth Healthcare Holdings Co., Ltd. (002044.SZ) - Growth Opportunities

• AI-driven health management: AI-related revenue exceeded CNY 215 million in 2024, creating a measurable new revenue stream.
• Strategic acquisition: In April 2025 the company acquired a 92.35% stake in Shandong Meining Aoya Health Consulting Co., Ltd., expanding service capabilities and regional reach.
• Diversified service mix: Expanding individual and group examination services aims to smooth seasonality and reduce reliance on single-channel income.
• Product innovation: Development of 'AI + health management' products targets a scalable, subscription-friendly business model for longitudinal care.
• Market sentiment: Market capitalization rose by 38.69% over the past year, reflecting stronger investor confidence.
• Analyst projections: Consensus forecasts imply earnings growth of 45.4% p.a. and revenue growth of 12.5% p.a. over the next three years.

• Potential near-term revenue drivers: monetization of AI diagnostics and subscriptions for continuous health management.
• Integration risk/opportunity: successful operational integration of Shandong Meining Aoya could accelerate cross-selling and regional penetration.
• Stability levers: larger share of group contracts and institutional clients can reduce per-visit revenue volatility.